Krystal Biotech Projects $389M Revenue for VYJUVEK in 2025
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 12 2026
0mins
Should l Buy KRYS?
Source: NASDAQ.COM
- Strong Financial Performance: Krystal Biotech anticipates fourth-quarter net product revenue for VYJUVEK to be between $106 million and $107 million, with full-year revenue projected at $388 million to $389 million, highlighting its market potential in rare disease therapies.
- Robust Cash Reserves: As of December 31, 2025, Krystal reported approximately $955 million in cash, cash equivalents, and investments, providing strong financial support for future R&D and market expansion initiatives.
- Clinical Trial Expansion: To expedite the development of KB801, Krystal has expanded enrollment in its ongoing registrational study from 27 to 60 patients, with top-line data expected before year-end 2026, demonstrating the company's proactive approach in rare disease drug development.
- Long-term Strategic Goals: Krystal aims to have at least four marketed rare disease medicines, including VYJUVEK, by 2030, reaching over 10,000 patients globally, reflecting its strong commitment to addressing the unmet needs of over 300 million people living with rare diseases worldwide.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy KRYS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on KRYS
Wall Street analysts forecast KRYS stock price to fall
9 Analyst Rating
8 Buy
1 Hold
0 Sell
Strong Buy
Current: 270.260
Low
198.00
Averages
229.25
High
278.00
Current: 270.260
Low
198.00
Averages
229.25
High
278.00
About KRYS
Krystal Biotech, Inc. is an integrated, commercial-stage biotechnology company. The Company is focused on the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs. Its product candidates in various stages of clinical and preclinical development include KB407, KB408, KB707, KB105, KB801, KB803, KB304 and KB301. Its commercial product, VYJUVEK, is a redosable gene therapy, and a genetic medicine approved in the United States and Europe for the treatment of dystrophic epidermolysis bullosa. KB407 is being developed for the treatment of Cystic Fibrosis. KB408 is being developed for the treatment of Alpha-1 Antitrypsin Deficiency, a rare lung disease. KB707 is being developed for the treatment of solid tumors. KB105 is being developed for TGM1-Deficient Autosomal Recessive Congenital Ichthyosis. KB803 is a redosable eye drop formulation of B-VEC, designed for the treatment of ocular complications.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Krystal Biotech to Announce Q4 Earnings on February 17
- Earnings Announcement: Krystal Biotech (KRYS) is set to release its Q4 2023 earnings on February 17 before market open, with consensus EPS estimates at $1.61, reflecting a modest year-over-year growth of 1.9%, indicating stable profitability.
- Revenue Expectations: The anticipated revenue for Q4 is $105.13 million, representing a 15.4% year-over-year increase, suggesting ongoing growth in market demand and product sales, which could bolster investor confidence.
- Historical Performance Review: Over the past two years, Krystal Biotech has only beaten EPS estimates 25% of the time and revenue estimates 50% of the time, indicating volatility in financial forecasting that may affect market expectations for future performance.
- Product Development Updates: Recently, Krystal Biotech showcased its KB707 program at the J.P. Morgan Healthcare Conference and received FDA RMAT status for its lung cancer therapy, highlighting potential in this area that could drive future revenue growth.
See More
Netflix Highlights a Rare Disease While Pearl Jam's Lead Singer Raises Funds for a Cure.
Nonprofit's Approach: A nonprofit organization is focusing on finding a cure for Epidermolysis Bullosa, a group of rare genetic skin disorders, by adopting a venture-capital-like strategy rather than traditional charity methods.
Goal Timeline: The organization aims to achieve its goal of finding a cure by the end of the decade.
See More
Soleus Capital Increases Stake in Celcuity
- Share Increase: Soleus Capital Management disclosed a purchase of 629,398 shares of Celcuity in an SEC filing, raising its total holdings to over 1.8 million shares valued at $180.36 million, indicating strong confidence in the company.
- Asset Allocation Shift: Celcuity now accounts for 6.7% of Soleus Capital's AUM, becoming its third-largest holding among 95 positions, reflecting investor interest in the biotechnology sector.
- Stock Performance: Celcuity's stock price surged 745% over the past year, significantly outperforming the S&P 500's 14.4% and NASDAQ Composite's 15.7%, highlighting strong market expectations for its future potential.
- Risk Advisory: Despite Celcuity's impressive stock performance, the company currently generates no revenue, necessitating caution from investors regarding inherent risks, as the stock's value is heavily reliant on drug approvals and future profitability prospects.
See More
Krystal Biotech Receives FDA RMAT Designation for KB707
- FDA Designation Progress: Krystal Biotech announced that its immunotherapy candidate KB707 has received the Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA, marking a significant milestone in its development for non-small cell lung cancer, potentially accelerating its clinical development timeline.
- Clinical Research Basis: This designation is based on early data from the ongoing KYANITE-1 study, which involves heavily pretreated advanced NSCLC patients receiving the gene therapy via inhalation, showing promising initial efficacy.
- Fast Track Advantages: With RMAT designation, KB707 becomes eligible for FDA's Fast Track and Breakthrough Therapy designations, which not only expedite the approval process but also facilitate closer and more frequent interactions with regulators to advance the drug's development.
- Innovative Mechanism of Action: KB707 is designed to target advanced or metastatic NSCLC by delivering cancer-targeting cytokines, interleukin-2 and interleukin-12, within the tumor microenvironment, showcasing its potential innovation and competitive edge in cancer treatment.
See More
Krystal Biotech Receives FDA RMAT Designation for KB707
- FDA Designation Progress: Krystal Biotech announced that its immunotherapy KB707 has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA, indicating the therapy's potential in treating advanced non-small cell lung cancer (NSCLC) and reflecting the urgent need for new therapies.
- Clinical Evidence Support: The company provided early clinical evidence from its ongoing KYANITE-1 study, demonstrating significant antitumor activity of KB707 in heavily pre-treated advanced NSCLC patients, including durable responses and clinically meaningful tumor reductions, enhancing its market prospects.
- Accelerated Development Benefits: The RMAT designation will provide KB707 with all the benefits of the FDA's Fast Track and Breakthrough Therapy designations, including rolling review and close FDA guidance, thereby shortening the potential approval timeline and enhancing the company's competitiveness in the biotech sector.
- Future Outlook: With ongoing enrollment in the KYANITE-1 study, Krystal Biotech plans to present more research details at upcoming scientific conferences, further driving its innovation and market impact in the gene therapy field.
See More
Krystal Biotech Rated as One of the Top Growth Stocks for the Next Decade
- Price Target Increase: Goldman Sachs analyst Andrea Tan raised Krystal Biotech's price target from $206 to $327, indicating a 16.7% upside from current levels, reflecting strong market confidence in its short-term growth potential.
- Strategic Program Development: The company is positioning itself for future growth with three registrational programs, KB801, KB803, and KB407, expected to support product launches around 2028, highlighting its strategic focus in the biotechnology sector.
- Investor Interest: Clear Street analyst William Maughan increased the price target from $288 to $338, offering a further 20.7% upside, emphasizing the sustained growth of Vyjuvek and the attractiveness of the company's expanding pipeline to investors.
- Neurotrophic Keratitis Market Potential: Analysts noted that KB801's potential in the neurotrophic keratitis market is a key focus for investors, with upcoming data releases expected to serve as significant catalysts for the stock's performance.
See More
Krystal Biotech to Announce Q4 Earnings on February 17
- Earnings Announcement: Krystal Biotech (KRYS) is set to release its Q4 2023 earnings on February 17 before market open, with consensus EPS estimates at $1.61, reflecting a modest year-over-year growth of 1.9%, indicating stable profitability.
- Revenue Expectations: The anticipated revenue for Q4 is $105.13 million, representing a 15.4% year-over-year increase, suggesting ongoing growth in market demand and product sales, which could bolster investor confidence.
- Historical Performance Review: Over the past two years, Krystal Biotech has only beaten EPS estimates 25% of the time and revenue estimates 50% of the time, indicating volatility in financial forecasting that may affect market expectations for future performance.
- Product Development Updates: Recently, Krystal Biotech showcased its KB707 program at the J.P. Morgan Healthcare Conference and received FDA RMAT status for its lung cancer therapy, highlighting potential in this area that could drive future revenue growth.
See More
Netflix Highlights a Rare Disease While Pearl Jam's Lead Singer Raises Funds for a Cure.
Nonprofit's Approach: A nonprofit organization is focusing on finding a cure for Epidermolysis Bullosa, a group of rare genetic skin disorders, by adopting a venture-capital-like strategy rather than traditional charity methods.
Goal Timeline: The organization aims to achieve its goal of finding a cure by the end of the decade.
See More
Soleus Capital Increases Stake in Celcuity
- Share Increase: Soleus Capital Management disclosed a purchase of 629,398 shares of Celcuity in an SEC filing, raising its total holdings to over 1.8 million shares valued at $180.36 million, indicating strong confidence in the company.
- Asset Allocation Shift: Celcuity now accounts for 6.7% of Soleus Capital's AUM, becoming its third-largest holding among 95 positions, reflecting investor interest in the biotechnology sector.
- Stock Performance: Celcuity's stock price surged 745% over the past year, significantly outperforming the S&P 500's 14.4% and NASDAQ Composite's 15.7%, highlighting strong market expectations for its future potential.
- Risk Advisory: Despite Celcuity's impressive stock performance, the company currently generates no revenue, necessitating caution from investors regarding inherent risks, as the stock's value is heavily reliant on drug approvals and future profitability prospects.
See More
Krystal Biotech Receives FDA RMAT Designation for KB707
- FDA Designation Progress: Krystal Biotech announced that its immunotherapy candidate KB707 has received the Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA, marking a significant milestone in its development for non-small cell lung cancer, potentially accelerating its clinical development timeline.
- Clinical Research Basis: This designation is based on early data from the ongoing KYANITE-1 study, which involves heavily pretreated advanced NSCLC patients receiving the gene therapy via inhalation, showing promising initial efficacy.
- Fast Track Advantages: With RMAT designation, KB707 becomes eligible for FDA's Fast Track and Breakthrough Therapy designations, which not only expedite the approval process but also facilitate closer and more frequent interactions with regulators to advance the drug's development.
- Innovative Mechanism of Action: KB707 is designed to target advanced or metastatic NSCLC by delivering cancer-targeting cytokines, interleukin-2 and interleukin-12, within the tumor microenvironment, showcasing its potential innovation and competitive edge in cancer treatment.
See More
Krystal Biotech Receives FDA RMAT Designation for KB707
- FDA Designation Progress: Krystal Biotech announced that its immunotherapy KB707 has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA, indicating the therapy's potential in treating advanced non-small cell lung cancer (NSCLC) and reflecting the urgent need for new therapies.
- Clinical Evidence Support: The company provided early clinical evidence from its ongoing KYANITE-1 study, demonstrating significant antitumor activity of KB707 in heavily pre-treated advanced NSCLC patients, including durable responses and clinically meaningful tumor reductions, enhancing its market prospects.
- Accelerated Development Benefits: The RMAT designation will provide KB707 with all the benefits of the FDA's Fast Track and Breakthrough Therapy designations, including rolling review and close FDA guidance, thereby shortening the potential approval timeline and enhancing the company's competitiveness in the biotech sector.
- Future Outlook: With ongoing enrollment in the KYANITE-1 study, Krystal Biotech plans to present more research details at upcoming scientific conferences, further driving its innovation and market impact in the gene therapy field.
See More
Krystal Biotech Rated as One of the Top Growth Stocks for the Next Decade
- Price Target Increase: Goldman Sachs analyst Andrea Tan raised Krystal Biotech's price target from $206 to $327, indicating a 16.7% upside from current levels, reflecting strong market confidence in its short-term growth potential.
- Strategic Program Development: The company is positioning itself for future growth with three registrational programs, KB801, KB803, and KB407, expected to support product launches around 2028, highlighting its strategic focus in the biotechnology sector.
- Investor Interest: Clear Street analyst William Maughan increased the price target from $288 to $338, offering a further 20.7% upside, emphasizing the sustained growth of Vyjuvek and the attractiveness of the company's expanding pipeline to investors.
- Neurotrophic Keratitis Market Potential: Analysts noted that KB801's potential in the neurotrophic keratitis market is a key focus for investors, with upcoming data releases expected to serve as significant catalysts for the stock's performance.
See More
